Navigation Links
InterMune to Present at 2010 Citi Health Care Conference
Date:5/21/2010

BRISBANE, Calif., May 21 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced that Steve Porter, M.D., Ph.D., Chief Medical Officer and Senior Vice President, Clinical Affairs of InterMune, will present at the 2010 Citi Health Care Conference in New York on May 26 at 3 p.m. EDT.

To access a live audio webcast of the presentation, investors and other interested parties may log on to the investor relations page of InterMune's corporate website at www.intermune.com.  The company recommends logging on to the site 15 minutes prior to the start of the presentation in order to register or download any necessary software.

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology.  InterMune has an R&D portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections.  The pulmonology portfolio includes pirfenidone for which InterMune has completed a Phase 3 program in patients with IPF (CAPACITY).  A Marketing Authorization Application (MAA) is under review by the European Medicines Agency (EMA).  The hepatology portfolio includes the HCV protease inhibitor compound danoprevir (also known as RG7227 or ITMN-191, partnered by Roche) that entered Phase 2b in

SOURCE InterMune, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. InterMune Receives FDA Complete Response Letter on Esbriet(TM) (Pirfenidone) New Drug Application
2. InterMune to Release First Quarter Financial Results on April 29
3. InterMune Announces Submission of MAA for Pirfenidone for the Treatment of Patients With IPF
4. InterMune Announces Proposed Public Offering of Common Stock
5. InterMune to Release Third Quarter Financial Results on November 5
6. InterMune Announces Collaboration With National Jewish Health on NIH-Supported Genetic Research in Idiopathic Pulmonary Fibrosis
7. InterMune to Present at Canaccord Adams Conference
8. InterMune Reports Second Quarter 2009 Financial Results and Business Highlights
9. InterMune to Release Second Quarter Financial Results on August 6
10. InterMune to Present at Goldman Sachs Healthcare Conference
11. InterMune Reports First Quarter 2009 Financial Results and Business Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014 /PRNewswire-iReach/ -- Maxim Peptide, a ... that are used solely in scientific experiments, is currently ... years in business, Maxim Peptide, which was created by ... a new and updated website that now features a ... has been updated with fascinating articles about peptide research, ...
(Date:7/11/2014)... Research and Markets  has announced the ... Global Industry Analysis, Size, Share, Growth, Trends and Forecast ... http://photos.prnewswire.com/prnh/20130307/600769 Transfection is ... or RNA) into cells. This technology helps the cells ... protein metabolism by affecting the nuclear genes. The transfection ...
(Date:7/11/2014)... GENEVA , July 11, 2014 ... pleased to announce the appointment of John P. ... Campus Biotech   in  Geneva . ... on Campus Biotech in Geneva , ... internationally recognised neuroscientists. John P. Donoghue , founder ...
(Date:7/11/2014)... 2014  Researchers have pioneered a revolutionary new ... technology, called Virtual Finger, allows scientists to move ... and synapses using the flat surface of their ... imaging studies orders of magnitude more efficient, saving ... across many areas of experimental biology. The software ...
Breaking Biology Technology:Maxim Peptide Celebrates Second Anniversary Online with an Updated Website and Special Deals Section 2International Transfection Technology Market - Industry Analysis, Size, Share, Growth, Trends and Forecast to 2019 2John P. Donoghue is Taking the Lead at the Wyss Center and is Appointed Professor at EPFL and University of Geneva 2John P. Donoghue is Taking the Lead at the Wyss Center and is Appointed Professor at EPFL and University of Geneva 3Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 2Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 3
... School of Economics and Political Science (LSE), Chatham ... on Emerging Nanotechnologies (PEN), an initiative of Woodrow ... Charitable Trusts, have been awarded a $587,000 European ... on regulating nanotechnologies in the European Union and ...
... Prevent HIV from Replicating, GAITHERSBURG, Md., Feb. ... gene therapies for HIV and genetic,diseases, presented results ... gene,therapy for the treatment of AIDS, at the ... in Boston, MA., "This appears to be ...
... Novavax, Inc. (Nasdaq:,NVAX) a clinical-stage vaccine company, ... Executive Officer, will be presenting at the,BIO CEO ... 12, 2008 at the,Waldorf=Astoria Hotel in New York. ... strategy, research and development progress. A link to ...
Cached Biology Technology:European Commission gives grant to investigate transatlantic oversight of nanotech 2European Commission gives grant to investigate transatlantic oversight of nanotech 3VIRxSYS Announces Interim Results from VRX496 Gene Therapy Phase II Trial 2
(Date:7/10/2014)... Colo. , June 27, 2014  The ... the National Institute of Standards and Technology (NIST) ... of its academic research and forensic science expert ... The Board is an element of the NIST,s ... members are among the first appointments made to ...
(Date:7/10/2014)... July 2, 2014  Unisys Corporation,s (NYSE: UIS ... Nederland N.V., today announced that it has been selected by ... manage a new Basic Provision Biometrics solution for penitentiaries across ... won the contract with a solution based on its open ... term of the contract is up to seven years, with ...
(Date:7/10/2014)... , July 3, 2014 Research ... addition of the "Global Gesture Recognition & ... - Forecasts to 2020" report to their ... Global Gesture Recognition & Touch-Less Sensing Market ... around for a while, but the companies were ...
Breaking Biology News(10 mins):Ten Members of the American Academy of Forensic Sciences Appointed to Forensic Science Standards Board (FSSB) 2Ten Members of the American Academy of Forensic Sciences Appointed to Forensic Science Standards Board (FSSB) 3Unisys Delivers New Basic Provision Biometrics Solution to Dutch Custodial Institutions Service 2Unisys Delivers New Basic Provision Biometrics Solution to Dutch Custodial Institutions Service 3Global Gesture Recognition & Touch-Less Sensing (2D, 3D, Ultrasonic, IR, Capacitive) Market - Forecasts to 2020 2
... 21 researchers from 11 nations, including professor Robert "JJ" Orth ... first-ever study of the risk of extinction for individual seagrass ... the International Union for the Conservation of Nature (IUCN), shows ... at an elevated risk of extinction, while 3 species qualify ...
... who reported not taking a daily prenatal vitamin immediately before ... as likely to have a child with an autism spectrum ... the associated risk rose to seven times as great when ... at the UC Davis MIND Institute has found. "Mothers ...
... body against infection don,t huff and puff, but some ... against infection don,t huff and puff, but some of ... steam engine. Weizmann Institute scientists have discovered a mechanism ... when the inflammatory mechanism that protects cells against viruses ...
Cached Biology News:New study provides global analysis of seagrass extinction risk 2Women who start prenatal vitamins early are less likely to have children with autism 2Women who start prenatal vitamins early are less likely to have children with autism 3Women who start prenatal vitamins early are less likely to have children with autism 4Immune system release valve 2
... Taura Syndrome Virus Coat Protein ... tested applications). ... MNDIPITNQN VVLSKNVTDN LFEVQDQALI ESLSRDVLLH NDSWTSSDDE ... terminal amino acids 25/100 of ...
Purified Mouse anti-Hu Actopaxin (pS8) Storage Temperature: Refrigerate(2 to 8C)...
... FastPlax Antibody is used to detect the ... surface of infected cells as early as ... of the FastPlax Titer Kit, which allows ... hours. The FastPlax Antibody can ...
b-Catenin (pSer675), phospho-specific...
Biology Products: